T2 Biosystems, Inc.
T2 Biosystems develops and sells diagnostic products for detecting pathogens, biomarkers, and abnormalities in various patient sample types. The company offers several diagnostic panels, including T2Candida, T2Bacteria, T2Resistance, and T2Biothreat. These tests detect blood stream infections, sepsis, candidemia, and biothreat pathogens. The company is also developing T2Cauris and T2Lyme panels for detecting Candida auris and Lyme disease bacteria, respectively. Headquartered in Massachusetts, the company was incorporated in 2006.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (100.00) is significantly higher than the sector mean (67.88).
- Price to book ratio (100.00) is significantly higher than the sector mean (9.96).
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (7.40%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (36.02).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |